Referencias

1. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 2002;16:352–61.
2. Sharma V, et al. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 2002;16:336–51
3. Mariani G. Unexpected keys in cell biochemistry imaging: some lessons from technetium-99m-sestamibi. J Nucl Med 1996;37:536–8.
4. Piwnica-Worms D, et al. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrana potential dependence. Circulation 1990;82:1826–38.
5. Delmon-Moingeon LI, et al. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198–202.
6. Piwnica-Worms D, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977–84.
7. Gottesman MM, et al. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
8. Piwnica-Worms D, et al. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 1995;34:12210–20.
9. Ballinger JR, et al. Technetium-99m-tetrofosmin as a substrate for Pglycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578–82.
10. Hanausek M, et al. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. PNAS 2001;98:11551–6.
11. Roomi MW, et al. Inhibition of 7,12-dimethylbenzanthracene-induced skin tumors by a nutrient mixture. Med Oncol 2008;25:333–40.
12. USP 32 NF 27. Official monographs. Technetium Tc 99m Sestamibi Injection. 2009;pp. 3671-2.
13. Belhaj-Tayeb H, et al. In vitro and in vivo study of ^99mTc-MIBI encapsulated in PEG-liposomes: a promising radiotracer for tumor imaging. Eur J Nucl Mol Imaging 2003;30: 502-9.
14. Liu Z, et al. Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using ^99mTc-labeled sestamibi and tetrofosmin. Nucl Med Biol 2005; 32:573-83.
15. Moretti JL, et al. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Mol Imaging 2005;32:836-42.
16. Erb P, et al. Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett 2005;100:68-72.
17. Blažić TM, et al. Apoptosis and immune response are responsible for the site-specific incidence of non-melanoma skin cancer. Med Hypotheses 2007;68:853-5.
18. Erb P, et al. Capítulo 22: Apoptosis and patogénesis of melanoma and nonmelanoma skin cancer. En: Sunlight, vitamin D and Skin cancer. Ed. Jörg Reichrath. 2008:283-295. Landes Bioscience and Springer Science+Business Media. Boston, MA, USA.
19. Aloj L, et al. Bcl-2 overexpression prevents ^99mTc-MIBI uptake in breast cancer cell lines. Eur J Nucl Mol Imaging 2004;31:521-7.
20. Del Vecchio S, Salvatore M. ^99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Mol Imaging 2004;31(Suppl. 1):S88-S96.